I-Orthovisc iyisisombululo esinyene noma esibucayi sesisindo esikhulu samangqamuzana, i-hyaluronate ye-sodium ehlanzekile kakhulu emanzini omzimba. I-Hyaluronan, esitholakala emzimbeni womuntu, igcoba amalunga futhi yenza njenge-absorber eshaqisayo. Nge- osteoarthritis , i-hyaluronan yemvelo isonakele.
I-Orthovisc ingenye ye-hyaluronates esebenzisa inqubo eyaziwa ngokuthi i- viscosupplementation .
I-Orthovisc iyi-viscosupplement engeyona isilwane ehlotshisiwe ejoyiwe ngqo emadolweni ukuze kuvuselelwe izakhiwo zokugcoba nokugcoba okwejwayelekile oketsheziweyo (ie, synovial fluid ).
Izinkomba ze-Orthovisc
I-Orthovisc yamukelwa yi-US Food and Drug Administration (FDA) ngoFebruwari 4, 2004, ekwelapheni ubuhlungu obuhlobene ne-knee osteoarthritis ezigulini ezihlulekile ukuthola ukukhululeka okwanele ngemithi yokwelashwa engaphezulu (isib. Ukuzivocavoca, ukwelashwa ngokomzimba) ukusetshenziswa kwe-analgesics elula, njenge- acetaminophen .
I-Orthovisc ibhekwa njengokwelashwa, hhayi umuthi, njengoba kunjalo nangamanye ama-hyaluronates asetshenziselwa i-viscosupplementation. I-Orthovisc ilawulwa njengochungechunge lwemijovo ye-intra-articular yamasonto amathathu kuya kwangu-4 (anikezwe kanye ngesonto). Ngokomkhiqizi we-Orthovisc, ingaveza imiphumela enenzuzo egcina amasonto angu-26.
Ukungafani
Abantu abane-hypersensitivity eyaziwayo emikhiqizo ye-hyaluronan akufanele baphathwe nge-Orthovisc noma noma yikuphi kwe-viscosupplements.
Futhi, abantu abanolwazi oluthinta izinyoni noma imikhiqizo yezinyoni akufanele basebenzise i-Orthovisc. (Qaphela: Lesi sixwayiso sisetshenziselwa yonke imikhiqizo ye-hyaluronan.) Abantu abanesifo ekuhlanganyeleni amadolo, ukutheleleka, noma isifo esikhumbeni lapho umjovo ozobekwa khona akufanele uphathwe nge-Orthovisc.
Imiphumela Ejwayelekile Yomphakathi kanye Nemicimbi Ebizayo
Izenzakalo ezivame kakhulu ezihlobene ne-Orthovisc yokwelapha ngesikhathi sokuhlolwa kwezemithi zihlanganisa i-arthralgia, ubuhlungu be-back, kanye nobuhlungu bekhanda. Ezinye izenzakalo ezimbi ziyizimpendulo zendawo yomjovo wendawo.
Ukuqapha nokuxwayiswa
Njenganoma imuphi umjovo we-intra-articular, kunconywa ukuthi isiguli sigweme imisebenzi enzima noma imisebenzi enesisindo esithatha isikhathi eside amahora angu-48. Futhi, kufanele kuqashelwe ukuthi ubuhlungu noma ukuvuvukala kungenzeka ngemuva komjovo, kodwa ngokuvamile kuzokwehla emva kwesikhathi esifushane. Okunye okuphawulekayo, ukuphepha nokusebenza kwe-Orthovisc akuzange kusungulwe kwabesifazane abakhulelwe, abashaya abesifazane noma izingane.
Okubalulekile
Amanye ama-viscosupplements avunyelwe i-FDA, kanye nosuku avunyelwe ngalo, afaka:
I-American Association of Orthopedic Surgeons (AAOS) ithe nakuba ezinye iziguli zibika ukukhululeka kwezimpawu ze-arthritis nge-viscosupplementation, le nqubo ayizange iboniswe ukuthi iguqule inqubo ye-arthritic noma ibuye ikhule isikhumba. Ukusebenza kwe-viscosupplementation ekwelapheni i-arthritis akucaci. Kuye kwaphakanyiswa ukuthi i-viscosupplementation inethuba elihle kakhulu lokuphumelela uma i-arthritis isesimweni sayo sokuqala (ie, i-knee osteoarthritis elula).
> Imithombo:
> I-Orthovisc. Anika Therapeutics.
> Orthovisc Orthovisc High i-Molecular Hyaluronan . US FDA. Okuqukethwe kungobo yomlando.
> Ulwazi lwe-Orthovisc lwesineke . US FDA.
> I-Viscosupplementation Treatment for Knee Arthritis. I-OrthoInfo (AAOS).